1. A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN (BV) AND LENALIDOMIDE (LEN) IN RELAPSED AND REFRACTORY (R/R) CUTANEOUS (CTCL) AND PERIPHERAL (PTCL) T‐CELL LYMPHOMAS: PRELIMINARY RESULTS OF A PHASE II TRIAL. (12th June 2019) Authors: William, B.M.; Abbasi, A.; Huang, Y.; Larbi, R.; Giali, R.; Yang, L.; Brammer, J.; Grantier, C.; Hoffman, C.; Ayyappan, S.; Baiocchi, R.; Epperla, N.; Christian, B.; Alinari, L.; Maddocks, K.; Chung, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 471 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. MAINTENANCE RITUXIMAB IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL IN MANTLE CELL LYMPHOMA PATIENTS RESPONDING TO INDUCTION THERAPY WITH BENDAMUSTINE + RITUXIMAB (BR). (12th June 2019) Authors: Hill, B.T.; Switchenko, J.M.; Martin, P.; Churnetski, M.C.; Sawalha, Y.; Goyal, S.; Shanmugasundaram, K.; Calzada, O.; Kolla, B.; Bachanova, V.; Gerson, J.N.; Barta, S.K.; Maldonado, E.; Gordon, M.; Danilov, A.; Grover, N.S.; Mathews, S.; Burkart, M.; Karmali, R.; Ghosh, N. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA EXPERIENCING FRONTLINE TREATMENT FAILURE: A MULTICENTER RETROSPECTIVE STUDY. (12th June 2019) Authors: Bond, D.A.; Switchenko, J.; Maddocks, K.; Churnetski, M.; Goyal, S.; Shanmugasundaram, K.; Calzada, O.; Kolla, B.; Bachanova, V.; Gerson, J.; Barta, S.; Hill, B.; Salwaha, Y.; Martin, P.; Maldonado, E.; Gordon, M.; Danilov, A.; Grover, N.; Mathews, S.; Burkart, M. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 408 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PHASE I DOSE‐ESCALATION STUDY OF VENETOCLAX PLUS BEAM FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR CHEMORESISTANT, RELAPSED/REFRACTORY, OR HIGH‐RISK NON‐HODGKIN'S LYMPHOMA (NHL); PRELIMINARY RESULTS. (12th June 2019) Authors: Maakaron, J.; Zhao, Q.; Puto, M.; Von Derau, R.; Robinson, J.; Brammer, J.; Penza, S.; Baiocchi, R.; Christian, B.; Maddocks, K.; Saad, A.; Wall, S.; Benson, D.; Efebera, Y.; Rosko, A.; Ayyappan, S.; Grieselhuber, N.; Vasu, S.; Larkin, K.; Epperla, N. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 528 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗